Traditionally creating optimized, stable cell lines has been a time-consuming and complex process. Drawing upon proprietary technology – AMSBIO can deliver the high-quality cell lines you need with a single customer-defined knock-in in just 25% of the time required with conventional approaches.
Using a patented FAST-HDR plasmid vector system – AMSBIO can dramatically speed vector construction and reduce the time required to successfully isolate modified clones following transfection.
Using modular plasmid backbones, in which key components are readily swappable, AMSBIO can rapidly implement customer-defined knock-in combinations. Fail-proof directional cloning of homology arms into the vector takes less than a day. Levering the power of CRISPR/Cas9 and homology-directed repair, the FAST-HDR plasmid vector system enables isolation of pure, successfully modified clones within just 2 weeks of transfection.
The efficiency of this process allows us to deliver a stable cell line with as many as three knock-ins months in as little as 30 days. Using the FAST-HDR plasmid vector system, AMSBIO can deliver a cell pool even more quickly.
For a wide range of applications including drug screening, differentiation studies and inducible expression studies, the specialists at AMSBIO can collaborate with you to develop an optimized, custom cell line to stably express your gene of interest. For further information on custom cell line development please visit https://www.amsbio.com/custom-cell-line-development/ or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / email@example.com.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.